These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 17539051)
41. Molecule of the month. Vorinostat. Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971 [No Abstract] [Full Text] [Related]
42. Clinical quality assurance in the pharmaceutical industry. Donahue JJ Cancer Treat Rep; 1985 Oct; 69(10):1195-7. PubMed ID: 4042098 [No Abstract] [Full Text] [Related]
43. When are "positive" clinical trials in oncology truly positive? Ocana A; Tannock IF J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576 [TBL] [Abstract][Full Text] [Related]
44. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Takimoto CH Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251 [TBL] [Abstract][Full Text] [Related]
48. Development of effective new treatments for multiple myeloma. Anderson KC; Pazdur R; Farrell AT J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064 [No Abstract] [Full Text] [Related]
49. [Recent proposals for early stage clinical trials of cancer]. Ohashi Y Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106 [TBL] [Abstract][Full Text] [Related]
51. Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development. Shea M; Ostermann L; Hohman R; Roberts S; Kozak M; Dull R; Allen J; Sigal E Nat Rev Drug Discov; 2016 Mar; 15(3):152. PubMed ID: 26931085 [No Abstract] [Full Text] [Related]
52. More trials, fewer tribulations. Eisenstein M Sci Am; 2014 Jul; 311(1):S9-11. PubMed ID: 24974700 [No Abstract] [Full Text] [Related]
53. Much has changed in cancer clinical trials in the past 10 years. Wujcik DM ONS Connect; 2012 Jul; 27(7):7. PubMed ID: 22855982 [No Abstract] [Full Text] [Related]
54. Role of the FDA in cancer therapy research. Young RS Semin Oncol; 1981 Dec; 8(4):447-52. PubMed ID: 7323818 [No Abstract] [Full Text] [Related]
55. Cancer drugs should add months, not weeks, say experts. Hoag H Nat Med; 2011 Jan; 17(1):7. PubMed ID: 21217655 [No Abstract] [Full Text] [Related]
56. Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface. Gastl G; Dittrich C Onkologie; 2003 Oct; 26 Suppl 6():IX. PubMed ID: 23570176 [No Abstract] [Full Text] [Related]
57. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. Schilsky RL J Clin Oncol; 2009 Aug; 27(23):3725-30. PubMed ID: 19581526 [No Abstract] [Full Text] [Related]
58. The trials and tribulations of doing drug research in children. Matsui D; Kwan C; Steer E; Rieder MJ CMAJ; 2003 Nov; 169(10):1033-4. PubMed ID: 14609972 [No Abstract] [Full Text] [Related]
59. Opportunities and challenges in the development of experimental drug combinations for cancer. Humphrey RW; Brockway-Lunardi LM; Bonk DT; Dohoney KM; Doroshow JH; Meech SJ; Ratain MJ; Topalian SL; Pardoll DM J Natl Cancer Inst; 2011 Aug; 103(16):1222-6. PubMed ID: 21765011 [TBL] [Abstract][Full Text] [Related]
60. Rethinking cancer clinical trials for the future. Galsky MD Future Oncol; 2014; 10(9):1545-7. PubMed ID: 25145425 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]